MYBPC3 and cardiomyopathy: Survival analysis for 57 TNNI3 p.Arg21Cys-related cardiomyopathy patients revealed a markedly lower age at the first adverse event as compared with 47 HCM patients with the MYBPC3 p.Arg502Trp mutation (Figure 2).